EFFECT OF VEDOLIZUMAB DOSE ESCALATION ON RECAPTURING RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

被引：9
|
作者：
Shivashankar, Raina
Ladd, Antonio H. Mendoza
Grace, Rory
Aberra, Faten
Lichtenstein, Gary R.
机构：
来源：
GASTROENTEROLOGY | 2017年 / 152卷 / 05期
关键词：
D O I：
10.1016/S0016-5085(17)30608-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
304
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [31] THE EFFECT OF VEDOLIZUMAB ON COLONIC MICROBIOTA COMPOSITION IN PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE
    Altomare, A.
    Rocchi, G.
    Balestrieri, P.
    Tullio, A.
    Putignani, L.
    Gori, M.
    Guarino, M. P. L.
    Cicala, M.
    DIGESTIVE AND LIVER DISEASE, 2023, 55 : S179 - S179
  • [32] Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease
    Shmidt, Eugenia
    Kochhar, Gursimran
    Hartke, Justin
    Chilukuri, Prianka
    Meserve, Joseph
    Chaudrey, Khadija
    Koliani-Pace, Jenna L.
    Hirten, Robert
    Faleck, David
    Barocas, Morris
    Luo, Michelle
    Lasch, Karen
    Boland, Brigid S.
    Singh, Siddharth
    Vande Casteele, Niels
    Sagi, Sashidhar Varma
    Fischer, Monika
    Chang, Shannon
    Bohm, Matthew
    Lukin, Dana
    Sultan, Keith
    Swaminath, Arun
    Hudesman, David
    Gupta, Nitin
    Kane, Sunanda
    Loftus, Edward V., Jr.
    Sandborn, William J.
    Siegel, Corey A.
    Sands, Bruce E.
    Colombel, Jean-Frederic
    Shen, Bo
    Dulai, Parambir S.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (11) : 2461 - 2467
  • [33] Adalimumab Concentrations Following Dose Escalation in Inflammatory Bowel Disease
    Jasurda, Jake
    McCabe, Robert
    Vaughn, Byron
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S437 - S438
  • [34] OUTCOMES OF DOSE ESCALATION WITH ADALIMUMAB (ADA) IN INFLAMMATORY BOWEL DISEASE
    Dillon, A.
    Rowan, C.
    Gibson, D.
    Keegan, D.
    Byrne, K.
    Mulcahy, H.
    Cullen, G.
    Doherty, G.
    GUT, 2013, 62
  • [35] PREDICTORS AND OUTCOMES OF USTEKINUMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE
    Petrov, Jessica C.
    Fine, Sean
    Al Bawardy, Badr
    GASTROENTEROLOGY, 2022, 162 (07) : S824 - S824
  • [36] Predictors and frequency of anti-TNF dose escalation in patients with inflammatory bowel disease
    Viazis, N.
    Koukouratos, T.
    Anastasiou, J.
    Saprikis, E.
    Kechagias, G.
    Katopodi, K.
    Mela, M.
    Karamanolis, D.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S224 - S224
  • [37] VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Haddley, K.
    DRUGS OF TODAY, 2014, 50 (04) : 309 - 319
  • [38] Vedolizumab (Entyvio) for Inflammatory Bowel Disease
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2014, 56 (1451): : 86 - 88
  • [39] Variability in Vedolizumab Exposure Between Patients With Inflammatory Bowel Disease
    Gils, Ann
    Dreesen, Erwin
    Peeters, Miet
    Brouwers, Els
    Ferrante, Marc
    Van Assche, Gert
    Vermeire, Severine
    GASTROENTEROLOGY, 2016, 150 (04) : S411 - S412
  • [40] Articular Manifestations in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
    Dupre, Anastasia
    Collins, Michael
    Carbonnel, Franck
    Mariette, Xavier
    Seror, Raphaele
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
12345